When the Acquirer Is a Stranger to the Industry: The PMI Risk No One Prices In

---

Two deals landed this week that share almost nothing on the surface — and everything underneath.

In South Korea, Harim Group, the country's largest poultry processor, was named preferred bidder for Homeplus Express, a supermarket chain operating under court-led restructuring. The price is reported at around ₩300 billion ($203 million). The strategic logic: Harim has spent decades building backward integration from chicken farms through feed mills and processing plants. Homeplus Express — with its 300+ locations — would finally close the loop at the consumer end. Farm to fork, literally.

On the same week, in a deal twelve times larger, India's Sun Pharma agreed to acquire US-listed Organon for $11.75 billion in an all-cash transaction. Organon — spun off from Merck in 2021 — specialises in women's health and biosimilars. Sun Pharma is primarily a generics powerhouse. The combined company would generate approximately $12.4 billion in revenues and rank among the top 25 pharmaceutical companies globally, while becoming the world's seventh largest biosimilar company (Organon Press Release, 2026.04.26; CNBC, 2026.04.27).

Both deals are strategically defensible. Both carry a specific category of risk that rarely appears in the deal model.

The Cultural Distance Variable

Academic research on post-acquisition performance has consistently identified cultural and organisational distance as a primary moderator of integration outcomes. King et al. (2004), in a meta-analysis of 93 post-acquisition performance studies published in the Strategic Management Journal, found that financial and strategic variables explained far less variance in acquisition outcomes than generally assumed — and that unmeasured moderators, particularly at the organisational level, consistently accounted for the gap (King, D.R., Dalton, D.R., Daily, C.M., & Covin, J.G., 2004, Strategic Management Journal, 25(2), 187–200).

Cartwright and Cooper (1993) specifically examined what they called "culture compatibility" in acquisitions, finding that the greater the gap between acquirer and target organisational cultures, the more likely the integration was to experience employee resistance, productivity decline, and leadership attrition — regardless of the financial logic of the deal (Cartwright, S. & Cooper, C.L., 1993, "The Role of Culture Compatibility in Successful Organizational Marriage," Academy of Management Executive, 7(2), 57–70).

Both the Harim-Homeplus and Sun Pharma-Organon transactions involve acquirers stepping into industries where their core operational DNA does not fully translate.

The Korea Parallel

South Korea has a long history of conglomerates acquiring companies in adjacent or unrelated industries — retail, healthcare, logistics — as part of diversification strategies. What the Harim case makes visible is a structural pattern: when a strong vertical integration rationale meets a distressed target under court supervision, the combined complexity of operational integration and financial rehabilitation creates a layered risk stack.

The Homeplus Express sale is not simply a change of ownership. Harim's management teams, used to supply chain efficiency in protein processing, will inherit store-level employee relations shaped by years of Homeplus's retail culture — including a union currently offering wage concessions to secure lender support (Seoul Economic Daily, 2026.05.01). The relational fabric of the target will arrive on Day 1 of integration, whether or not the acquirer has a plan for it.

RaymondsIndex data across 3,109 Korean companies shows that 78% of integration delays are attributable not to financial mismatch but to relational breakdown — the collapse of trust, communication channels, and informal coordination mechanisms that no balance sheet reflects.

What Both Deals Need Now

In cross-industry acquisitions, the standard PMI playbook — rationalise costs, harmonise systems, communicate the vision — tends to underperform precisely because it assumes a shared operating language that does not exist.

What actually matters in the first 90 days: mapping the relational infrastructure of the target, not just its org chart. Who are the informal connectors? Which middle managers hold institutional knowledge that will walk out the door if onboarding goes wrong? Where are the customer relationships anchored — in the brand, or in specific people?

Neither Sun Pharma nor Harim has disclosed its Day 1 integration plan. That is, itself, information.

#M&A #PMI #CrossIndustry #KoreaMA #Integration #Pharma #Retail